

Monterrey, Mexico. October 21, 2013 – Alpek, S.A.B. de C.V. (BMV: ALPEK)

Alpek reports 3Q13 EBITDA of U.S. \$158 million

Selected Financial Information

(U.S. \$ Millions)

	3Q13	2Q13	3Q12	(% 3Q'13 vs.)		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Total Volume (ktons)	1,002	998	1,076	-	(7)	2,957	3,139	(6)
Polyester and Polyester Products	786	783	857	-	(8)	2,334	2,519	(7)
Plastics and Chemicals	215	216	220	-	(2)	623	620	-
Consolidated Revenues	1,783	1,811	1,795	(2)	(1)	5,419	5,603	(3)
Polyester and Polyester Products	1,367	1,380	1,399	(1)	(2)	4,169	4,390	(5)
Plastics and Chemicals	416	431	396	(4)	5	1,250	1,213	3
Consolidated EBITDA⁽¹⁾	158	122	190	29	(17)	440	587	(25)
Polyester and Polyester Products	113	72	140	56	(19)	304	423	(28)
Plastics and Chemicals	44	49	50	(9)	(12)	132	164	(19)
Profit Attributable to Controlling Portion	41	(71)	87	158	(52)	31	247	(87)
CAPEX and Acquisitions	30	60	36	(51)	(16)	156	75	108
Net Debt	662	644	618	3	7	662	618	7
Net Debt/LTM EBITDA ⁽²⁾	1.1	1.1	0.8			1.1	0.8	
Interest Coverage ⁽²⁾	6.1	5.9	6.7			6.1	6.7	

(1) Includes U.S \$27 million Cape Fear expense provision. Proforma EBITDA is U.S. \$149 million in 2Q13 and U.S. \$467 million YTD'13.

(2) Times: Last 12 months.

Operating & Financial Highlights (3Q13)

ALPEK	<ul style="list-style-type: none"> +29% EBITDA growth vs. 2Q13 (+6% excluding the 2Q13 Cape Fear expense provision), but 10% below original estimates U.S. \$135 million EBITDA expected in 4Q13 due to seasonality and a slower than anticipated recovery in caprolactam (CPL) and polyester export market conditions Average debt maturity extended to 8.4 years through debt refinancing
Polyester	<ul style="list-style-type: none"> Global polyester markets outside of North America pressured by recent volatility in Asian polyester margin recovery As planned, all plant operations ceased at Cape Fear on September 30, 2013 JV agreement signed with “United Petrochemical Company” in Russia
Plastics & Chemicals	<ul style="list-style-type: none"> Higher than anticipated YTD EBITDA in Plastics & Chemicals, excluding caprolactam CPL margins remained below expectations but continued their gradual recovery Technology license agreement signed with DSM Fiber Intermediates to enhance Alpek’s CPL cost competitiveness

This release contains forward-looking information based on numerous variables and assumptions that are inherently uncertain. They involve judgments with respect to, among other things, future economic, competitive and financial market conditions and future business decisions, all of which are difficult or impossible to predict accurately. Accordingly, results could vary from those set forth in this release. The report presents unaudited financial information based on International Financial Reporting Standards (IFRS) in effect in Mexico beginning January 2012. Figures are stated in nominal Mexican pesos (\$) and in current U.S. Dollars (U.S. \$), as indicated. Where applicable, peso amounts were translated into U.S. Dollars using the average exchange rate of the months during which operations were recorded. Financial ratios are calculated in U.S. Dollars. Due to the rounding up of figures, small differences may occur when calculating percent changes from one period to the other.

Message from the CEO

As we moved into the second half of 2013, the recovery in some of our markets and products was slower than anticipated. Alpek's third quarter EBITDA was higher than the previous quarter, but results were below our guidance which was based on a stronger recovery in caprolactam and polyester export markets towards the end of the year.

During the third quarter, the gradual upward trend in Asian polyester margins that began after 4Q12 shifted unexpectedly and increased pressure on global polyester markets outside of North America. Moreover, this year's global CPL margins have consistently been lower than expected. Taking into account the most recent industry trends and the lower contribution of the fourth quarter due to seasonality, we estimate 4Q13 consolidated EBITDA of U.S. \$135 million.

The operating efficiency initiatives we are currently implementing are underscored by the prevailing market conditions. The closure of Cape Fear (CF) and consolidation of our polyester operations is progressing as planned. All plant operations at CF ceased on September 30, 2013 and the transition process involving other Alpek facilities is ongoing. In addition, we recently signed a technology license agreement with DSM Fiber Intermediates (DSM) to enhance our CPL facility, which is one of the lowest-cost plants in the world. DSM is a leading global CPL technology provider based in The Netherlands. The technology licensed from DSM will allow us to capture U.S. \$9 million in estimated annual cash savings, beginning in the second half of 2014, by reducing feedstock consumption and maximizing the efficiency of certain production processes.

Capital expenditures (Capex) through September totaled U.S. \$156 million. Strategic projects including the Cosoleacaque cogeneration facility and the green-field PTA/PET site in Corpus Christi comprised more than 80% of accumulated Capex.

We have also selectively pursued new investment opportunities. We are very excited by the prospect of the JV agreement signed with United Petrochemical Company (UPC), a subsidiary of Sistema JSFC (Sistema), for the potential construction of an IntegRex[®] PTA/PET plant in Russia. This project represents an important milestone as it would be Alpek's first venture outside of the Americas and the first time we lever our IntegRex[®] technology as a vehicle for international expansion.

We remain fully committed to the implementation of other strategic projects that have yet to reach their investment stage. The technical specification process of our Altamira cogeneration facility is underway and we continue to actively engage potential partners to finalize the definition stage of our MEG (Monoethyleneglycol) backward integration project.

On the financing front, we concluded our comprehensive refinancing initiative with the issuance of U.S. \$300 million 5.375% ten-year Senior Notes during the third quarter. Over the last twelve months, we issued a total of U.S. \$950 million ten-year Senior Notes and extended our average debt maturity to more than 8 years by refinancing shorter term debt. As a result, Alpek's debt amortizations between September 30, 2013 and 2021 now total U.S. \$141 million or one-third of the Company's 3Q13 cash balance. Furthermore, Net Leverage remains low at 1.1 times and Interest Coverage, excluding one-time refinancing charges, reached 8.6 times.

Results by Business Segment

Polyester

(PTA, PET, Polyester fibers – 77% of Alpek's Net Sales)

Alpek's third quarter polyester prices were 6% higher year-on-year as a result of the upward trend sustained between June 2012 and February 2013. Quarter-on-quarter, average polyester prices decreased 1% in 3Q13. Lower oil and petrochemical feedstock prices (e.g. Paraxylene and MEG), beginning in March 2013, were reflected in the consecutive polyester price decreases posted in the second and third quarters. The rise in oil and petrochemical feedstock prices at the end of 3Q13 contributed to reduce the quarter-on-quarter polyester price decrease from 5% in the second quarter to 1% in the third quarter. It is important to note that while price volatility is relevant for the top line, its effect on margins is mitigated by Alpek's cost-plus pricing.

Polyester volume decreased 8% year-over-year during 3Q13, but was virtually unchanged compared with 2Q13. Alpek sustained polyester volume at 786 Ktons in the third quarter amid the effective shutdown of all operations at its Cape Fear site and two major hurricanes affecting Mexico during September.

Segment EBITDA was U.S. \$113 million in the third quarter, down 19% year-on-year, but 56% higher when compared to the second quarter. The 56% EBITDA growth reflects a lower comparable base in 2Q13 as a result of the one-time U.S. \$27 million Cape Fear closure expense provision. Excluding the effect of the 2Q13 expense provision, comparable Polyester EBITDA grew 14% quarter-on-quarter. Although Polyester EBITDA improved from the second to the third quarter, Alpek had anticipated stronger results in the second half of the year. The gradual recovery observed since 4Q12 in Asian polyester margins shifted unexpectedly in 3Q13 and pressured global polyester markets outside of North America.

Plastics and Chemicals (P&C)

(Polypropylene (PP), Expandable Polystyrene (EPS), Caprolactam (CPL), Other products – 23% of Alpek's Net Sales)

3Q13 Plastics & Chemicals volume was 2% lower year-on-year. Quarter-on-quarter, segment volume was stable (215 Ktons) following the 13% volume increase posted in 2Q13. Volume growth in Plastics & Chemicals products such as EPS and caprolactam was offset by a 6% decline in polypropylene. Raw material price volatility and lower price expectations negatively impacted polypropylene demand towards the end of the third quarter. However, incremental exports to the United States and Canada, as well as the start of the Mexican electronics and appliances packaging season boosted EPS volume 14%, compared with 2Q13.

Plastics & Chemicals EBITDA was U.S. \$44 million in the third quarter, down 12% year-on-year or 9% lower when compared to 2Q13. The quarter-on-quarter decrease in segment EBITDA was caused by weaker polypropylene volume and lower margins to propylene. It is important to note that year-to-date Plastics & Chemicals EBITDA, excluding caprolactam, has exceeded original estimates as a result of stronger EPS and polypropylene margins. However, caprolactam margin recovery has been much slower than anticipated after incremental capacity in China caused an abrupt contraction since the second half of 2012.

Consolidated Financial Results

Net Sales: Net sales for the third quarter totaled U.S. \$1,783 million, down 1% compared with 3Q12 and 2% lower than 2Q13. Polyester revenues decreased 2% year-on-year driven by an 8% decrease in volume that was partially offset by a 6% increase in average polyester prices. In contrast, Plastics and Chemicals net sales increased 5% on an annual basis as a result of a 7% increase in average prices that was partially offset by a 2% decrease in volume. On a quarterly basis, net sales decreased 1% and 4% for Polyester and Plastics and Chemicals, respectively. Volume was flat, but average dollar prices for both Polyester and Plastics and Chemicals decreased between 2Q13 and 3Q13 following lower oil and petrochemical feedstock prices.

EBITDA: 3Q13 EBITDA was U.S. \$158 million, down 17% year-on-year but 29% higher when compared to the second quarter. The 29% EBITDA growth reflects a lower comparable base in 2Q13 as a result of the one-time U.S. \$27 million Cape Fear closure expense provision. Excluding the 2Q13 expense provision for better comparability, consolidated EBITDA grew 6% quarter-on-quarter and EBITDA per ton increased from U.S. \$150 in 2Q13 to U.S. \$158 in 3Q13. Although 3Q13 EBITDA was higher than 2Q13, original estimates were based on a stronger recovery in caprolactam and polyester export markets throughout the second half of 2013 which did not fully materialize.

Profit Attributable to Controlling Portion: The Profit Attributable to the Controlling Portion totaled U.S. \$41 million during the third quarter, down 52% year-on-year as a result of a 21% decrease in operating income and a 17% increase in comprehensive financing expenses which include U.S. \$18.3 million one-time charges associated with the debt prepayments carried out in 3Q13. On a quarterly basis, the Profit Attributable to the Controlling Portion increased 158% as a result of the net impact related to the announced closure of the Cape Fear site in 2Q13. Excluding the Cape Fear effect, the Profit Attributable to the Controlling Portion totaled U.S. \$43 million in the second quarter.

Capital Expenditures: Capital expenditures were U.S. \$30 million in 3Q13, with funds used primarily for the construction of the cogeneration plant and a second payment related to the agreements signed with M&G. Capital expenditures also include asset replacements and other smaller capital projects. Total CAPEX during the nine month period ended September 30, 2013 was U.S. \$156 million.

Net Debt: Consolidated Net Debt as of September 30, 2013 totaled U.S. \$662 million, up 7% year-on-year and 3% higher when compared to 2Q13. Gross Debt as of September 30, 2013 totaled U.S. \$1,104 million, up 2% year-on-year and 1% higher than 2Q13. Alpek issued a total of US\$950 million ten-year Senior Notes during the last twelve months and extended its average debt maturity to 8.4 years by refinancing shorter term debt. Financial ratios as of September 30, 2013 were: Net Debt to LTM EBITDA of 1.1 times and Interest coverage of 6.1 times. Interest coverage excluding one-time charges associated with debt prepayments was 8.6 times.

Other Developments

Dividends: Alpek completed the second dividend payment approved by shareholders at its Ordinary Shareholder's Meeting on February 28, 2013. A first payment amounting to U.S. \$0.032 per share was made on March 8, 2013, and a second payment amounting to U.S. \$0.022 per share was made on September 19, 2013. This year's cash dividend totaled U.S. \$0.054 per share, equivalent to U.S. \$114 million.

Appendix A - Tables

TABLE 1 | VOLUME (KTONS)

	3Q13	2Q13	3Q12	(%) 3Q13 vs.		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Total Volume	1,002	998	1,076	-	(7)	2,957	3,139	(6)
Polyester	786	783	857	-	(8)	2,334	2,519	(7)
Plastics and Chemicals	215	216	220	-	(2)	623	620	-

TABLE 2 | PRICE CHANGES (%)

	(%) 3Q13 vs.		YTD'13 vs. YTD'12
	2Q13	3Q12	
Polyester			
Avg. Ps. Prices	3	4	(2)
Avg. U.S. \$ Prices	(1)	6	2
Plastics and Chemicals			
Avg. Ps. Prices	1	5	(2)
Avg. U.S. \$ Prices	(3)	7	3
Total			
Avg. Ps. Prices	2	5	(1)
Avg. U.S. \$ Prices	(2)	7	3

TABLE 3 | REVENUES

	3Q13	2Q13	3Q12	(%) 3Q'13 vs.		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Total Revenues								
Ps. Millions	23,208	22,616	23,817	3	(3)	69,108	74,375	(7)
U.S. \$ Millions	1,783	1,811	1,795	(2)	(1)	5,419	5,603	(3)
Domestic Revenues								
Ps. Millions	8,041	8,657	8,602	(7)	(7)	24,879	26,648	(7)
U.S. \$ Millions	618	693	648	(11)	(5)	1,952	2,009	(3)
Foreign Revenues								
Ps. Millions	15,167	13,959	15,215	9	-	44,229	47,727	(7)
U.S. \$ Millions	1,165	1,118	1,146	4	2	3,467	3,594	(4)
Foreign / Total (%)	65	62	64			64	64	

TABLE 4 | OPERATING INCOME AND EBITDA

	3Q13	2Q13	3Q12	(%) 3Q'13 vs.		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Operating Income								
Ps. Millions	1,532	(999)	1,973	253	(22)	2,056	6,175	(67)
U.S. \$ Millions	118	(75)	149	256	(21)	162	466	(65)
EBITDA								
Ps. Millions	2,064	1,525	2,519	35	(18)	5,624	7,775	(28)
U.S. \$ Millions	158	122	190	29	(17)	440	587	(25)

TABLE 5 | COMPREHENSIVE FINANCING (EXPENSE) / INCOME (CF(E)/I) (U.S. \$ Millions)

	3Q13	2Q13	3Q12	(%) 3Q'13 vs.		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Financial Expenses	(29)	(22)	(44)	(31)	34	(71)	(107)	34
Financial Income	3	3	8	5	(62)	9	20	(54)
Net Financial Expenses	(26)	(19)	(36)	(36)	27	(62)	(87)	29
Fx Gains (Losses)	1	(8)	4	112	(78)	-	19	(100)
Interest Rate Swaps	(8)	-	-	(100)	(100)	(8)	-	(100)
Gas & Comm. Derivatives	-	-	4	-	(100)	-	-	-
CF(E)/ I	(33)	(27)	(28)	(23)	(17)	(69)	(68)	(2)

TABLE 6 | NET INCOME (U.S \$ Millions)

	3Q13	2Q13	3Q12	(%) 3Q'13 vs.		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Consolidated Net Income	56	(60)	105	193	(47)	73	292	(75)
Non-Controlling Portion	14	11	18	27	(19)	42	45	(7)
Controlling Portion	41	(71)	87	158	(52)	31	247	(87)
Earnings per Share (U.S. Dollars)	0.02	(0.03)	0.04	158	(52)	0.01	0.13	(88)
Avg. Outstanding Shares (Millions)	2,118	2,118	2,118			2,118	1,956	8

TABLE 7 | CASH FLOW (U.S. \$ Millions)

	3Q13	2Q13	3Q12	(% 3Q'13 vs.)		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
EBITDA	158	122	190	29	(17)	440	587	(25)
Net Working Capital & Others	(24)	86	16	(128)	(253)	(29)	(125)	76
Capital Expenditures & Acq.	(30)	(60)	(36)	51	16	(156)	(75)	(108)
Financial Expenses	(35)	(22)	(36)	(64)	-	(74)	(83)	11
Income tax	(21)	(23)	(30)	8	30	(62)	(112)	45
Dividends	(70)	-	(94)	(100)	26	(165)	(176)	6
Increase in stockholder's equity	-	-	-	-	-	-	749	(100)
Payment affiliated companies	-	-	(2)	-	100	-	(221)	100
Other Sources / Uses	4	(1)	18	675	(76)	1	26	(97)
Decrease (Increase) in Net Debt	(17)	103	27	(117)	(163)	(46)	570	(108)

TABLE 8 | STATEMENT OF FINANCIAL POSITION & FINANCIAL RATIOS (U.S. \$ Millions)

	3Q13	2Q13	3Q12
Assets	4,654	4,683	4,717
Liabilities	2,472	2,534	2,465
Stockholders' Equity	2,183	2,149	2,252
Net Debt	662	644	618
Net Debt/EBITDA*	1.1	1.1	0.8
Interest Coverage*	6.1	5.9	6.7

* Times: last 12 months.

Polyester and Polyester Products

TABLE 9 | REVENUES

	3Q13	2Q13	3Q12	(% 3Q'13 vs.)		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Total Revenues								
P.s. Millions	17,799	17,231	18,559	3	(4)	53,170	58,262	(9)
U.S. \$ Millions	1,367	1,380	1,399	(1)	(2)	4,169	4,390	(5)
Domestic Revenues								
P.s. Millions	4,266	4,694	5,018	(9)	(15)	13,508	15,367	(12)
U.S. \$ Millions	328	376	378	(13)	(13)	1,060	1,160	(9)
Foreign Revenues								
P.s. Millions	13,533	12,537	13,541	8	-	39,662	42,895	(8)
U.S. \$ Millions	1,039	1,004	1,020	4	2	3,109	3,230	(4)
Foreign / Total (%)	76	73	73			75	74	

TABLE 10 | OPERATING INCOME AND EBITDA

	3Q13	2Q13	3Q12	(% 3Q'13 vs.)		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Operating Income								
P.s. Millions	1,047	(1,522)	1,424	169	(26)	624	4,337	(86)
U.S. \$ Millions	80	(117)	108	169	(25)	49	328	(85)
EBITDA								
P.s. Millions	1,471	894	1,852	65	(21)	3,878	5,597	(31)
U.S. \$ Millions	113	72	140	56	(19)	304	423	(28)

Plastics & Chemicals

TABLE 11 | REVENUES

	3Q13	2Q13	3Q12	(% 3Q'13 vs.)		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Total Revenues								
P.s. Millions	5,409	5,385	5,258	-	3	15,938	16,113	(1)
U.S. \$ Millions	416	431	396	(4)	5	1,250	1,213	3
Domestic Revenues								
P.s. Millions	3,775	3,963	3,584	(5)	5	11,370	11,281	1
U.S. \$ Millions	290	317	270	(9)	8	892	849	5
Foreign Revenues								
P.s. Millions	1,634	1,422	1,674	15	(2)	4,568	4,832	(5)
U.S. \$ Millions	125	114	126	10	-	358	364	(2)
Foreign / Total (%)	30	26	32			29	30	

TABLE 12 | OPERATING INCOME AND EBITDA

	3Q13	2Q13	3Q12	(% 3Q'13 vs.)		YTD'13	YTD'12	Ch.%
				2Q13	3Q12			
Operating Income								
P.s. Millions	469	507	551	(7)	(15)	1,378	1,840	(25)
U.S. \$ Millions	36	40	42	(11)	(13)	108	139	(22)
EBITDA								
P.s. Millions	577	614	668	(6)	(14)	1,692	2,180	(22)
U.S. \$ Millions	44	49	50	(9)	(12)	132	164	(19)

Appendix B – Financial Statements

ALPEK, S.A.B DE C.V. and Subsidiaries

BALANCE SHEET

Information in millions of Mexican Pesos

	Sep 13	Jun 13	Sep 12	(% Sep 13 vs.)	
				Jun 13	Sep 12
ASSETS					
CURRENT ASSETS:					
Cash and cash equivalents	5,749	5,855	5,943	(2)	(3)
Trade accounts receivable	11,609	11,390	11,271	2	3
Other accounts and notes receivable	1,471	1,520	1,279	(3)	15
Inventories	11,694	11,707	10,857	-	8
Other current assets	1,726	1,720	1,779	-	(3)
Total current assets	32,249	32,192	31,129	-	4
Investment in shares	67	79	104	(15)	(36)
Property, plant and equipment, net	24,769	25,228	26,386	(2)	(6)
Goodwill and intangible assets, net	2,936	2,899	2,257	1	30
Other non-current assets	541	591	743	(8)	(27)
Total assets	60,562	60,989	60,619	(1)	-
LIABILITIES AND STOCKHOLDER'S EQUITY					
CURRENT LIABILITIES:					
Current portion of long-term debt	260	260	927	-	(72)
Bank loans and notes payable	399	511	347	(22)	15
Suppliers	9,948	10,177	9,628	(2)	3
Other current liabilities	3,063	3,618	2,636	(15)	16
Total current liabilities	13,670	14,566	13,538	(6)	1
NON-CURRENT LIABILITIES:					
Long-term debt	13,406	13,256	12,378	1	8
Deferred income taxes	3,782	3,765	4,449	-	(15)
Other liabilities	118	229	273	(48)	(57)
Employees' benefits	1,183	1,181	1,043	-	13
Total liabilities	32,159	32,997	31,681	(3)	2
EQUITY:					
Controlling portion:					
Capital stock	6,052	6,052	6,052	-	-
Share premium	9,071	9,071	9,071	-	-
Contributed capital	15,123	15,123	15,123	-	-
Earned surplus	9,944	9,395	10,505	6	(5)
Stockholders' equity controlling portion	25,067	24,518	25,628	2	(2)
Non-controlling portion	3,336	3,474	3,310	(4)	1
Total equity	28,403	27,992	28,938	1	(2)
Total liabilities and equity	60,562	60,989	60,619	(1)	-

ALPEK, S.A.B DE C.V. and Subsidiaries

STATEMENT OF INCOME

Information in millions of Mexican Pesos

	3Q13	2Q13	3Q12	YTD '13	YTD '12	3Q13 vs. (%)	
						2Q13	3Q12
Net sales	23,208	22,616	23,817	69,108	74,375	3	(3)
Domestic	8,041	8,657	8,602	24,879	26,648	(7)	(7)
Export	15,167	13,959	15,215	44,229	47,727	9	-
Cost of sales	(21,138)	(20,644)	(21,451)	(63,113)	(66,873)	(2)	1
Gross profit	2,070	1,972	2,366	5,995	7,502	5	(13)
Operating expenses and others	(538)	(2,971)	(393)	(3,939)	(1,327)	82	(37)
Operating income (loss)	1,532	(999)	1,973	2,056	6,175	253	(22)
Comprehensive financing expense, net	(432)	(336)	(372)	(885)	(897)	(29)	(16)
Equity in income (loss) of associates	(11)	(4)	(13)	(26)	(28)	(175)	15
Profit (loss) before income tax	1,089	(1,339)	1,588	1,145	5,250	181	(31)
Income tax	(364)	553	(201)	(226)	(1,385)	(166)	(81)
Consolidated net income (loss)	725	(786)	1,387	919	3,865	192	(48)
Profit (loss) attributable to Controlling portion	538	(928)	1,152	385	3,267	158	(53)
Profit attributable to Non-controlling portion	187	142	235	534	598	32	(20)